Results 61 to 70 of about 289,170 (184)

Effects of preoperative chemotherapy on neuroblastoma with MYCN amplification: a surgeon's perspective. [PDF]

World J Pediatr Surg, 2020
Background Preoperative chemotherapy plays an important role in the surgical management of unresectable neuroblastoma. Its response to chemotherapy has been variable due to the tumor’s heterogeneity.
Chui C.
europepmc   +5 more sources

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

American Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac, Audrey Bidet, Elise Chapiro, Nathalie Douet‐Guilbert, Jean‐Baptiste Gaillard, Nada Assaf, Nathalie Auger, Hend Chaker, Jasmine Chauzeix, Inge Govaerts, Hippolyte Guérineau, Christine Lefebvre, Pauline Roynard, Hélène Guermouche, Lucienne Michaux, Marie‐Bérengère Troadec, Lauren Véronèse   +16 more
wiley   +1 more source

Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain

Frontiers in Oncology, 2019
Background: Amplification of the MYCN oncogene is the most unfavorable genetic factor in neuroblastoma patients. However, knowledge about the clinical impact of low-level multiplication of MYCN is still insufficient.
Katarzyna Szewczyk, Aleksandra Wieczorek, Aleksandra Wieczorek, Wojciech Młynarski, Szymon Janczar, Mariola Woszczyk, Zuzanna Gamrot, Radosław Chaber, Mariusz Wysocki, Monika Pogorzała, Mirosław Bik-Multanowski, Walentyna Balwierz, Walentyna Balwierz   +12 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Application of the FISH method and high-density SNP arrays to assess genetic changes in neuroblastoma—research by one institute

Acta Biochimica Polonica
Neuroblastoma is the most common extracranial solid tumor in children. Amplification of the MYCN gene has been observed in approximately 20%–30% of tumors.
Dorota Winnicka, Paulina Skowera, Magdalena Stelmach, Borys Styka, Monika Lejman   +4 more
doaj   +1 more source

Neuroblastomas in Eastern China: a retrospective series study of 275 cases in a regional center [PDF]

PeerJ, 2018
Purpose Most studies on neuroblastoma (NB) have been conducted in Western countries or Japan. The objective of our study was to analyze clinical and pathological features, MYCN status, surgical methods, and prognosis in Chinese NB patients.
Yangyang Ma, Jicui Zheng, Jiayan Feng, Lian Chen, Kuiran Dong, Xianmin Xiao   +5 more
doaj   +2 more sources

The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors

Medicinal Research Reviews, EarlyView.
ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti, Camilla Tavani, Elena Somenza, Nicolas Tassone, Antonio d'Amati, Marta Turati, Roberto Ronca   +6 more
wiley   +1 more source

Clinical prognostic risk model optimization based on vascular density in neuroblastoma

Pediatric Investigation, EarlyView.
This study integrates lymphatic vessel density with the International Neuroblastoma Risk Group (INRG) risk classification to develop a more accurate clinical prognostic model for neuroblastoma, demonstrating superior discrimination, calibration, and clinical net benefit compared with the INRG risk classification alone.
Qiaoyin Liu, Jialin Cui, Dong Ren, Lei Yang, Xinyu Wang, Jiatong Xu, Yifan Liu, Cong Zhang, Haoyu Xu, Lejian He, Huanmin Wang, Haiyan Cheng, Guoshuang Feng, Xin Ni, Shengcai Wang, Yaqiong Jin   +15 more
wiley   +1 more source

Letting the breaks off MYCN

, 2016
Much of our understanding of the biology of MYCN amplification in neuroblastoma is based on the exploration of transcriptional activity of MYCN.
MILAZZO, GIORGIO, Narayan, Nisha, PERINI, GIOVANNI, Paul G Ekert, Ekert, Paul G., Giorgio Milazzo, Nisha Narayan, Giovanni Perini   +7 more
core   +1 more source

Evaluation of MYCN immunohistochemistry as a cost-effective surrogate for MYCN genetic testing

, 2022
Background: Background: MYCN amplified neuroblastomas are associated with poor prognosis. Fluorescence in-situ Hybridization (FISH) is the recommended technique to identify MYCN amplification.
Aditya Jadav, Charvy Rana, Aanchal Kakkar, V.K. Iyer, Iyer, V.K., Bakhshi, Sameer, Rana, Charvy, Burra Shivani Srivastava, Antony, Abin, Srivastava, Burra Shivani, Sandeep Agarwala, Sameer Bakhshi, Jadav, Aditya, Aditya Gupta, Kakkar, Aanchal, Agarwala, Sandeep, Abin Antony, Gupta, Aditya   +17 more
core   +1 more source